[Long-term treatment with calcium antagonists: advantageous effects and risks].
van Zwieten
P A
PA
Afd. Farmacotherapie, Academisch Medisch Centrum, Amsterdam.
Tijssen
J G
JG
Lie
K I
KI
de Leeuw
P W
PW
D002121:Calcium Channel Blockers / Q000009:adverse effects / Q000627:therapeutic use*; D018849:Controlled Clinical Trials as Topic; D006801:Humans; D006973:Hypertension / Q000150:complications / Q000188:drug therapy*; D009203:Myocardial Infarction / Q000209:etiology; D009543:Nifedipine / Q000009:adverse effects; D012189:Retrospective Studies; D012307:Risk Factors; D014700:Verapamil / Q000009:adverse effects
D002121:Calcium Channel Blockers; D014700:Verapamil; D009543:Nifedipine
Langdurige behandeling met calciumantagonisten: nuttige effecten en risico's.